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Prostate Volume has Prognostic Value Only in Pathologic T2 
Radical Prostatectomy Specimens
The objective of this study was to evaluate the prognostic roles of the prostate volume, 
tumor volume, and tumor percentage as a function of the pathologic T stage in radical 
prostatectomy specimens. This study included 259 patients who underwent radical 
prostatectomy between 2005 and 2010. The mean follow-up period was 41.2 months. In 
all of the specimens, prostate volume (P = 0.021), the Gleason score (P = 0.035), and 
seminal vesicle invasion (P = 0.012) were independent predictors of biochemical recurrence 
(BCR). In the T2 group, multivariate analysis showed that the BCR was significantly 
associated with prostate specific antigen (PSA) (P = 0.028), a lower prostate volume (P = 
0.004), and the Gleason score (P = 0.040). The Kaplan-Meier survival curve showed that a 
smaller prostate volume was significantly associated with a greater risk of BCR (< 30 vs      
≥ 30 mL; P = 0.010). In the T3 group, patients with seminal vesicle invasion had a 
significantly shorter mean BCR-free survival (P = 0.030). In this study, tumor volume and 
tumor percentage did not predict BCR. Notably, a lower prostate volume is an independent 
predictor for BCR only in the organ-confined radical prostatectomy specimens. But, 
prostate volume could not predict BCR in most locally advanced tumors. 
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INTRODUCTION
Recently, Korea has faced a very rapid change and increase in 
the incidence of prostate cancer, which draws much attention 
in public health. According to the Korea National Cancer Inci-
dence Database, the incidence for prostate cancer increased 
annually by 13.4% from 1999 to 2007 (1, 2). The early detection 
of prostate cancer with prostate specific antigen (PSA) testing 
allows many patients the option of radical treatment with cura-
tive intent. However, approximately 25% of patients will devel-
op a post-operative biochemical recurrence (BCR) by the time 
of the 5-yr follow-up, and the 10-yr risk of BCR is approximately 
35% (3-6). The prognosis after radical prostatectomy is usually 
based on clinical findings (pre-operative PSA level and the PSA 
doubling time) and pathologic findings (the Gleason score, sur-
gical margin status, extra-prostatic extension, and seminal vesi-
cle invasion) (7, 8).
  Several investigators have suggested that tumor volume and 
tumor percentage are independent predictors of recurrence (9-
11). Freedland et al. (12) have suggested that prostate volume 
may be an important prognostic variable to predict BCR and 
men with smaller prostates have more high-grade cancers, more 
advanced disease, and at greater risk of progression after radi-
cal prostatectomy. However, others have argued that prostate 
volume, tumor volume, and tumor percentage are not indepen-
dent predictors of prostate cancer progression when incorporat-
ing the more readily determined tumor grade and stage in the 
analysis (13, 14). Despite the biological relevance of tumor bur-
den, the status of prostate volume, tumor volume, and tumor 
percentage as independent predictors of outcome after radical 
prostatectomy has not been well-defined. Furthermore, late in 
the PSA era, no study has investigated the importance of pros-
tate volume, tumor volume, and tumor percentage in predict-
ing outcome, especially in patients with pathologically organ-
confined tumors.
  In this study we evaluated and compared prostate volume, 
tumor volume, and tumor percentage as independent predic-
tors of BCR after radical prostatectomy by pathologic T stage. 
This is the first study to examine the role of prostate volume, tu-
mor volume, and tumor percentage as it relates to BCR in men 
stratified by pathologic T stage. 
MATERIALS AND METHODS
Study population
Two hundred fifty-nine Korean men, 49-80 yr of age, with clini-
cally localized or locally advanced adenocarcinoma of the pros-
tate were included in this retrospective study. The patients un-Cho I-C, et al.  •  Prognostic Significance of Prostate Volume in Prostate Cancer
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derwent radical prostatectomy at our institution between Feb-
ruary 2005 and February 2010. We excluded from analysis pa-
tients who received hormone or radiation therapy before sur-
gery, used 5α-reductase inhibitor therapy, had pathologic T0 
disease, and those with incomplete clinical or pathologic data. 
After the radical prostatectomies, patients were followed by mea-
surements of serum PSA levels at ≤ 3 month intervals for the first 
2 yr and every 6 months thereafter. A BCR was defined as a post-
operative serum PSA of at least 0.2 ng/mL, increasing at least         
1 subsequent estimation. Irrespective of the pathologic findings, 
suggesting a poor prognosis, none of the patients received any 
adjuvant therapy until the BCR was detected.
Specimen collection
Fresh specimens were weighed and fresh weight was used as a 
surrogate for total prostate volume. Actual prostate weight was 
measured after removal at radical prostatectomy, and after re-
moving the seminal vesicles, with the exception of the base. The 
apex and bladder base were amputated. Prostate volume was 
determined by assuming that prostatic tissue was composed pri-
marily of water and converting weight in gram to mL (1 g H2O = 
1 mL H2O). The specimens were then fixed in formalin and se-
rially-sectioned at 3-mm intervals in a plane perpendicular to 
the rectal surface and embedded in paraffin. Specimens were 
then cut at a thickness of 5 μm and examined microscopically. 
One professional uropathologist examined slides without knowl-
edge of patient outcome. The tumor area was marked on the 
glass slide, the diameter was measured, the vol% was calculat-
ed, and the specimen was graded according to the Gleason sys-
tem (15). Tumor volume was determined using a visual estima-
tion. The area of the tumor was measured in x and y diameters 
and multiplied by the depth, based on the presence of tumor in 
subsequent sections and the thickness of the sections. The sum 
total of all foci of tumor was the estimated tumor volume. This 
method of visual estimation was previously described and vali-
dated in other studies (16). Tumor involvement of each slide was 
estimated by the percentage of the slide containing tumor. Esti-
mation of the tumor percentage for the entire prostate was com-
pleted by summing each individual slide and averaging the re-
sults from all slides that were analyzed. The individual slides 
were also examined for the presence of standard pathologic in-
dices, including pathologic stage, margin status, Gleason score, 
lymph node involvement, seminal vesicle invasion, and extra-
capsular extension of the tumor.
Statistical analysis
Patients were divided into two groups on the basis of the patho-
logic T stage (T2 and T3). A Cox proportional hazard model with 
stepwise selection of the co-variates was used to determine 
whether or not the prostate volume, tumor volume, tumor per-
centage, PSA, Gleason score, surgical margin status, or seminal 
vesicle invasion predicted the BCR. Univariate and multivariate 
analyses were performed for each group to determine the sig-
nificance of the prostate volume, tumor volume, or tumor per-
centage as predictors of BCR within these subsets. Patients were 
stratified by prostate volume (≥ 30 mL or < 30 mL). Cut-off points 
for the variable prostate volume was chosen to separate the pa-
tient populations by median value. A BCR-free survival curves 
was plotted according to the Kaplan–Meier method. A log-rank 
test was applied to determine the relationship between prog-
nostic markers and BCR. The levels of statistical significance 
were set at a P < 0.05 (two-sided), and the Statistical Package for 
the Social Sciences for Windows (version 12.0) was used for sta-
tistical analysis.
Ethics statement
The study protocol was approved by the institutional review 
board at the National Cancer Center Hospital (Goyang, Korea; 
IRB registration number-NCC NCS 05-049). An informed con-
sent was obtained from each patient. 
RESULTS
Clinico-pathologic characteristics
Two hundred fifty-nine patients were included in this study. The 
median duration of follow-up after radical prostatectomy was 
40 months (range, 6-63 months). The data on patient age, PSA, 
pathologic features, and BCR are summarized in Table 1. Dur-
ing the present observation period, BCR developed in 59 of 259 
patients (22.8%). Within the entire group, 29.7% of the patients 
Table 1. Patient characteristics stratified by organ confinement
Variables
Organ confinement
P 
value Organ-confined  
(n = 182)
Extra-prostatic  
(n = 77)
Mean (range) age (yr) 64.3 (50-80) 64.6 (49-78) 0.520
Mean (range) PSA (ng/mL) 17.5 (0.8-173.6) 24.7 (3.7-95.8) 0.082
Prostate volume (range) (mL) 33.2 (10.6-91.0) 28.6 (6.0-88.8) 0.032
Tumor volume (range) (mL) 4.9 (0.3-40.2) 8.4 (0.4-28.8) 0.001
Tumor percentage (range) (%) 14.2 (2.0-80.0) 27.9 (5.0-80.0) < 0.001
Biopsy GS (%)
   5-7
   8-10
 
172 (94.5)
10 (5.5)
 
56 (72.5)
21 (27.5)
< 0.001
Post-operative GS (%)
   5-7
   8-10
 
145 (97.3)
4 (2.7)
 
42 (79.2)
11 (20.8)
0.004
Surgical margin status (%)
   Positive
   Negative
 
52 (28.6)
130 (71.4)
 
27 (35.3)
50 (64.7)
0.470
Seminal vesicle invasion (%)
   Positive
   Negative
 
0 (0.0)
182 (100.0)
 
25 (33.3)
51 (66.7)
< 0.001
BCR (%)
   Occurred
   Did not occur
 
23 (12.6)
159 (87.4)
 
36 (47.1)
41 (52.9)
< 0.001
PSA, prostate-specific antigen; GS, Gleason score; BCR, biochemical recurrence. Cho I-C, et al.  •  Prognostic Significance of Prostate Volume in Prostate Cancer
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had stage pT3, 30.5% were surgical margin-positive, and 9.6% 
had evidence of seminal vesicle invasion. The mean serum PSA 
value for patients with organ-confined and extra-prostatic dis-
ease was 17.5 and 24.7 ng/mL, respectively. Extra-prostatic dis-
ease was associated with biopsy Gleason score (P < 0.001), post-
operative Gleason score (P = 0.003), seminal vesicle invasion (P 
< 0.001), BCR (P < 0.001), lower prostate volume (P = 0.032), 
higher tumor volume (P = 0.001), and higher tumor percentage 
(P < 0.001).
The impact of prostate volume, tumor volume, and tumor 
percentage on BCR in all specimens
There were BCRs in 59 of 259 patients (22.8%). We evaluated the 
predictive value of several clinicopathologic factors for BCR. By 
univariate Cox proportional hazards analysis, most of the pa-
rameters, except surgical margin status (P = 0.324), significantly 
influenced the time to BCR. Multivariate Cox proportional haz-
ards analysis revealed that BCR was significantly associated with 
a prostate volume (hazard ratio [HR] = 0.919, P = 0.021), biopsy 
Gleason score (HR = 2.150, P = 0.035), seminal vesicle invasion 
(HR = 6.650, P = 0.012), and extra-prostatic extension (HR = 2.006, 
P = 0.048; Table 2). The Kaplan-Meier survival curve showed that 
a smaller prostate volume was significantly associated with a 
greater risk of BCR (comparing < 30 vs ≥ 30 mL; P = 0.001; Fig. 1A).
The impact of prostate volume, tumor volume, and tumor 
percentage on BCR in stage pT2 specimens
There were BCRs in 23 of 182 patients (12.6%) with stage pT2. 
Based on univariate Cox proportional hazards analysis, the PSA 
(P = 0.006), prostate volume (P = 0.007), and high biopsy Glea-
son score (P = 0.015) significantly influenced the time to BCR. 
Multivariate Cox proportional hazards analysis revealed that 
BCR was significantly associated with a PSA level (HR = 1.016, P 
= 0.028), prostate volume (HR = 0.885, P = 0.004), and biopsy 
Gleason score (HR = 2.121, P = 0.040; Table 3). The Kaplan-Mei-
er survival curve showed that a smaller prostate volume was sig-
nificantly associated with a greater risk of BCR (< 30 vs ≥ 30 mL; 
P = 0.010; Fig. 1B).
The impact of prostate volume, tumor volume, and tumor 
percentage on BCR in stage pT3 specimens
There were BCRs in 36 of 77 patients (47.1%) with stage pT3. 
Based on univariate Cox proportional hazards analysis, the PSA 
(P < 0.001), tumor volume (P = 0.020), tumor percentage (P = 
Table 2. Univariate and multivariate analyses of prognostic factors for biochemical recurrence in all specimens (n = 259)
Variables
Univariate Multivariate
HR (95% CI) P value HR (95% CI) P value
PSA 1.015 (1.009-1.023) < 0.001 1.003 (0.983-1.024) 0.748
Prostate volume 0.951 (0.919-0.980) 0.003 0.918 (0.855-0.987) 0.021
Tumor volume 1.051 (1.014-1.089) 0.008 1.109 (0.885-1.388) 0.365
Tumor percentage 1.035 (1.020-1.047) < 0.001 0.991 (0.917-1.071) 0.823
Biopsy GS (5-7 vs 8-10*) 4.830 (2.473-9.435) < 0.001 2.150 (1.576-2.941) 0.035
Post-operative GS (5-7 vs 8-10*)   4.255 (1.558-11.623) 0.007 1.626 (0.451-5.865) 0.459
Surgical margin status (negative vs positive*) 1.393 (0.721-2.694) 0.324 - -
Seminal vesicle invasion (absence vs presence*)   7.893 (3.997-15.591) < 0.001   6.644 (1.573-28.061) 0.012
Extra-prostatic extension (absence vs presence*) 4.440 (2.328-8.479) < 0.001 2.005 (1.202-2.835) 0.048
*Reference category. PSA, prostate-specific antigen; GS, Gleason score; HR, hazard ratio; CI, confidence interval.
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Fig. 1. BCR-free survival curves according to the prostate volume in all (A) and pT2 (B) specimens.
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0.001), high Gleason score (P = 0.023), and seminal vesicle in-
vasion (P = 0.001) significantly influenced the time to BCR. Mul-
tivariate Cox proportional hazards analysis revealed that BCR 
was significantly associated with only seminal vesicle invasion 
(HR = 2.665, P = 0.030; Table 4). 
DISCUSSION
The ability to predict disease recurrence after a radical prosta-
tectomy is important because this will allow for the identifica-
tion of patients who may be candidates for adjuvant therapy. 
Numerous studies, mostly performed before the widespread 
use of PSA testing, have shown that the pre-operative PSA level, 
Gleason score, seminal vesicle invasion, surgical margin status, 
and pathologic stage are independent predictors of cancer re-
currence after treatment with radical prostatectomy (17). In the 
present study, the prostate volume, tumor volume, and tumor 
percentage represented independent variables in the progres-
sion of prostate cancer after radical prostatectomy. These factors 
predict BCR in men who undergo a radical prostatectomy with 
clinically localized prostate cancer (12, 18, 19). Though these 
variables have been analyzed independently in the past, the re-
lationship has not been previously examined in men stratified 
by pathologic T stage.
  Our results revealed that BCR was significantly associated with 
prostate volume, biopsy Gleason score, and seminal vesicle in-
vasion in all specimens. When grouping data by pathologic stage, 
the univariate model for pT2 showed that PSA, prostate volume, 
and biopsy Gleason score were significant factors; however, tu-
mor volume, tumor percentage, post-operative Gleason score, 
and surgical margin status were not significant factors. The mul-
tivariate model showed that PSA, prostate volume, and biopsy 
Gleason score were independent predictors of cancer recurrence. 
The univariate model for pT3 showed that PSA, tumor volume, 
tumor percentage, biopsy Gleason score, and seminal vesicle 
invasion were significant factors, but prostate volume, post-op-
erative Gleason score, and surgical margin status were not sig-
nificant factors. The multivariate model demonstrated the sig-
nificance of seminal vesicle invasion when controlling for PSA, 
tumor volume, tumor percentage, and biopsy Gleason score.
  In agreement with previous reports (20, 21), we showed that 
men with smaller prostates were at a significantly higher risk of 
BCR. The reason for this remains unknown; however, many po-
tential explanations exist. First, it has been suggested that men 
with smaller prostates may have lower levels of testosterone, 
which has been shown to correlate with more aggressive pros-
tate cancer (22). Second, men with larger prostates had their 
tumors detected earlier because of PSA-driven biopsies result-
ing from PSA elevation from an enlarged gland. This lead-time 
bias would be expected to result in better outcomes (23). As 
shown in Table 1, the extra-prostatic group had a higher PSA 
than the organ-confined group. The PSA range was 3.7-95.8 ng/
mL. Thus, a PSA-driven biopsy group that had a large portion of 
benign tissue is difficult to be included. Third, a tumor within a 
small prostate has to migrate a lesser distance to escape the pros-
tatic capsule, as demonstrated by Yadav et al. (24), who showed 
Table 4. Univariate and multivariate analyses of prognostic factors for biochemical recurrence in stage pT3 specimens (n = 77)
Variables
Univariate Multivariate
HR (95% CI) P value HR (95% CI) P value
PSA 1.032 (1.015-1.048) < 0.001 1.020 (0.998-1.042) 0.077
Prostate volume 0.988 (0.947-1.031) 0.593 - -
Tumor volume 1.067 (1.010-1.127) 0.020 0.987 (0.864-1.128) 0.849
Tumor percentage 1.030 (1.011-1.048) 0.001 1.025 (0.982-1.069) 0.258
Biopsy GS (5-7 vs 8-10*) 2.579 (1.137-5.849) 0.023 1.666 (0.634-4.376) 0.301
Post-operative GS (5-7 vs 8-10*) 2.110 (0.634-7.021) 0.223 - -
Surgical margin status (negative vs positive*) 1.376 (0.610-3.104) 0.443 - -
Seminal vesicle invasion (absence vs presence*)   4.395 (1.904-10.145) 0.001 2.665 (1.273-6.706) 0.030
*Reference category. PSA, prostate-specific antigen; GS, Gleason score; HR, hazard ratio; CI, confidence interval.
Table 3. Univariate and multivariate analyses of prognostic factors for biochemical recurrence in stage pT2 specimens (n = 182)
Variables
Univariate Multivariate
HR (95% CI) P value HR (95% CI) P value
PSA 1.014 (1.003-1.026) 0.007 1.016 (1.002-1.031) 0.028
Prostate volume 0.902 (0.843-0.965) 0.005 0.881 (0.811-0.959) 0.004
Tumor volume 0.983 (0.889-1.088) 0.748 - -
Tumor percentage 1.016 (0.985-1.046) 0.264 - -
Biopsy GS (5-7 vs 8-10*)   4.953 (1.392-17.623) 0.015 2.119 (1.438-3.011) 0.040
Post-operative GS (5-7 vs 8-10*)   4.598 (0.574-36.884) 0.154 - -
Surgical margin status (negative vs positive*) 1.039 (0.328-3.286) 0.948 - -
*Reference category. PSA, prostate-specific antigen; GS, Gleason score; HR, hazard ratio; CI, confidence interval.Cho I-C, et al.  •  Prognostic Significance of Prostate Volume in Prostate Cancer
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that decreased prostate volume is a predictor of extra-prostatic 
extension. It is likely that a combination of these factors leads to 
a greater chance of BCR after treatment for men with smaller 
prostate volume. The most important ﬁnding in our study was 
obtained from the analysis of prostate volume stratified by patho-
logic T stage. Our data showed that prostate volume was not 
prognostic in the pT3 group.
  Extra-prostatic extension is an important prognostic factor, 
and that was expected far stronger than other prognostic factors, 
such as the prostate volume. In pT2 specimens, as a continuous 
variable, prostate volume was significantly associated with BCR 
(HR, 0.881; P = 0.004). The reduction in BCR risk may initially 
seem unimpressive; however, when considered in the context 
with other variables, it becomes more signiﬁcant. The prognos-
tic value of PSA in this model had a HR of 1.016; however, when 
the inverse was used, the HR was 0.984. Taking the reciprocal of 
PSA showed, as expected, that a decrease in PSA was predictive 
of decreased BCR risk. Interestingly, the predictive value is simi-
lar to that of prostate volume. PSA is a major factor in the stratiﬁ-
cation of risk for BCR for patients with prostate cancer (3, 25). 
Prostate volume may offer additional information that should 
be considered when counseling patients about their risk of BCR 
after radical prostatectomy, especially in organ-confined cases.
  In the current study, survival analyses using the prostate vol-
ume categories were provided in all and pT2 settings. Our stra-
tiﬁcation and analysis of prostate volume in subgroups < 30 and 
≥ 30 mL, is one of only a few studies to analyze prostate volume 
in a range that has immediate clinical relevance.
  In the present, retrospective, single-center study performed 
late in the PSA era, we found that prostate volume was a signifi-
cant predictive factor in the entire cohort of patients undergo-
ing radical prostatectomy for localized prostate cancer. Patients 
with lower prostate volume had a greater risk of BCR compared 
with patients with higher prostate volume. On multivariate anal-
ysis, prostate volume remained a significant factor in patients 
with pT2 prostate cancer. In those with a pT3, the prostate vol-
ume was not significantly associated with BCR, reflecting that 
the pT3 group is relatively low volume.
  The present findings differ from previous studies which found 
the tumor volume and tumor percentage to be significant pre-
dictors of BCR after radical prostatectomy (26-29). In the all sub-
group analysis, we found that tumor volume and tumor percent-
age were not independent predictors of cancer recurrence on 
multivariate analysis when controlling for other variables. Nel-
son et al. (28) concluded that tumor volume is an independent 
predictor of BCR in 431 men treated by radical prostatectomy. In 
that study, the mean tumor volume was associated with patho-
logic stage and was significantly different between patients with 
and without recurrence (6.8 and 2.6 mL, respectively). Based on 
multivariate analysis, tumor volume predicted BCR when con-
sidered as a continuous variable. Recent findings by Merrill et 
al. (14) in a large population undergoing radical prostatectomy 
for localized prostate cancer again confirmed this observation, 
finding that regardless of tumor volume, low-risk patients had a 
low rate of cancer recurrence. Notably, they found that tumor 
volume was a significant independent predictor of BCR in pa-
tients with a GS ≥ 7. Manoharan et al. (27) and Carvalhal et al. (26) 
reported tumor percentage to be an independent predictor of 
BCR. In contrast, the present findings are consistent with the 
findings of Epstein et al. (13), who examined 185 men with clini-
cal stage B prostate cancer and found that the tumor volume and 
tumor percentage did not provide independent prognostic in-
formation in a stepwise regression analysis; however, Gleason 
score and surgical margin status were independent predictors of 
recurrence. In our study, the tumor volume and tumor percent-
age were not meaningful for organ-confined cancers; however, 
the prognostic potential of tumor volume and tumor percentage 
was proposed for locally advanced cancers in univariate analyses.
  The interpretation of these results may vary; however, the prog-
nostic value of prostate volume is clearly present. It is important 
to note, our results suggest that some of the value of prostate vol-
ume was composed of lead time bias during the PSA era. Fur-
thermore, anatomic and biologic factors are strongly related to 
the association between prostate volume and prognosis. 
  In the case of pT3, we suggest that the tumor volume or tumor 
percentage can reflect the degree of extra-prostatic tumor exten-
sion indirectly. Thus, the tumor volume or tumor percentage 
has some prognostic role in pathologic-extra-prostatic disease. 
These are the reasons that the prostate volume, tumor volume, 
and tumor percentage should be analyzed separately depend-
ing on the pathologic stage.
  This conclusion has several clinical implications for the treat-
ment of patients with pT2 prostate cancer. First, regardless of 
other factors, patients with a low PSA and a high prostate volume 
are at low risk for BCR, and does not appear to place the patient 
in a higher risk group at the time of radical prostatectomy. There-
fore, routine resection of the neurovascular bundles is not rec-
ommended, and adjuvant therapy is of little benefit. Second, 
recognizing the limitations of tumor volume and tumor percent-
age in accurately predicting the BCR in every case, it seems like-
ly that tumor volume or tumor percentage alone would not jus-
tify adjuvant therapy.
  A number of factors may contribute to the variation between 
the findings of the current study and earlier studies. First, this is 
the first study to examine the role of prostate volume, tumor vol-
ume, and tumor percentage as it relates to BCR in men stratified 
by pathologic T stage. Second, in the current study, unlike exist-
ing studies, a well-defined and relatively homogeneous group 
of patients was subjected. In a number of earlier studies, a het-
erogeneous group of patients with pathologic stages ranging 
from pT1-pT4 was used, with some studies including patients 
with lymph node metastasis. As a result, substantial variation in Cho I-C, et al.  •  Prognostic Significance of Prostate Volume in Prostate Cancer
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the risk of BCR would relate to tumor stage and would potential-
ly contribute to a weakening of the prognostic value of the pros-
tate volume, tumor volume, and tumor percentage.
  There were several limitations to this study. First, a sample size 
of 259 men in such a common disease as prostate cancer is not 
sufficiently large. Second, our follow-up time was relatively short 
(median, 40.0 months). Extending the follow-up period by revis-
iting this study in 5 yr might provide stronger evidence for our 
conclusions. Third, our conclusions addressed the predictive 
values of prostate volume, tumor volume, and tumor percent-
age in the post-operative patient only. It would be beneficial to 
compare the pre-operative biopsy volume in this same popula-
tion to identify useful correlations in predicting BCR.
  The results of this study suggest that a lower prostate volume 
is a significant and independent predictor for BCR only in the 
organ-confined radical prostatectomy specimens. In contrast, 
prostate volume will not predict BCR in most locally advanced 
tumors. Additionally, tumor volume and tumor percentage 
could have some prognostic roles in pathologic extra-prostatic 
disease. 
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